CVKD
Cadrenal Therapeutics, Inc. Common Stock
Industry
Biotechnology
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Loading...
Open
11.70
Mkt cap
19M
Volume
125K
High
12.09
P/E Ratio
-1.66
52-wk high
32.55
Low
10.20
Div yield
N/A
52-wk low
5.40

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.